Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Employees

103

Sector

Biotechnology & Medical Research

Calendar

18/03 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
16/26/16	1.370 $	+7.03%	29,09,365
15/26/15	1.280 $	+3.23%	14,09,746
14/26/14	1.240 $	+3.33%	15,92,565
13/26/13	1.200 $	+1.69%	15,29,921
12/26/12	1.180 $	+0.85%	17,37,536

Delayed Quote Nasdaq, January 17, 2026 at 02:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.370USD

Average target price

2.920USD

Spread / Average Target

+113.14%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
1.370 ^USD	+7.03%		+17.09%	+19.13%

16/01	Lexicon Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-15-2026 12:00 PM
12/01	Lexicon Pharmaceuticals provides a business and pipeline update at the 44th annual J.P. Morgan healthcare conference	RE

Capitalization	50Cr 43Cr 40Cr 37Cr 69Cr 4.52TCr 75Cr 459.6Cr 181.22Cr 2.15TCr 186.7Cr 182.86Cr 7.87TCr	P/E ratio 2025 *	-8.18x	P/E ratio 2026 *	-5.17x
Enterprise value	50Cr 43Cr 40Cr 37Cr 69Cr 4.52TCr 75Cr 459.6Cr 181.22Cr 2.15TCr 186.7Cr 182.86Cr 7.87TCr	EV / Sales 2025 *	10.5x	EV / Sales 2026 *	23.7x
Free-Float	98.44%	Yield 2025 *	-	Yield 2026 *	-

16/01	Lexicon Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-15-2026 12:00 PM
12/01	Lexicon Pharmaceuticals provides a business and pipeline update at the 44th annual J.P. Morgan healthcare conference	RE
19/12	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) dropped from NASDAQ Biotechnology Index	CI
10/12	Lexicon Pharmaceuticals, Inc. Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Ayl-Coa Synthetase 5 Reinforcing the Scientific Rationale for Lx9851	CI
05/12	Lexicon Pharmaceuticals, Inc. Announces Clinical Data on Adipose Distribution in Non-Diabetic Patients to Be Presented At the 2025 Cardio Vascular Clinical Trialists Forum	CI
05/12	Clinical data on effect of sotagliflozin on adipose distribution in non-diabetic patients	RE
20/11	Lexicon Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 05:00 PM
09/11	Lexicon Pharmaceuticals, Inc. Announces Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure Without Diabetes Presented At American Heart Association Annual Scientific Sessions 2025	CI
07/11	Lexicon Pharmaceuticals Inc files for offering of up to $75 million of common stock - SEC filing	RE
07/11	Relay Therapeutics, Inc. Appoint Board and Committee, Effective November 4, 2025	CI
07/11	Lexicon Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 06, 2025
07/11	Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
06/11	Lexicon Pharma Q3 net loss narrows as R&D costs drops	RE

07/11	Relay Therapeutics, Inc. Appoint Board and Committee, Effective November 4, 2025	CI
05/25/05	Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2	MT
22/24/22	HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating	MT
22/24/22	Sector Update: Health Care Stocks Gain in Late Afternoon	MT
17/24/17	HC Wainwright Initiates Lexicon Pharmaceuticals With Buy Rating, $10 Price Target	MT

Lexicon Pharmaceuticals, Inc. Share Price

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Valuation: Lexicon Pharmaceuticals, Inc.

Chart: Lexicon Pharmaceuticals, Inc.

Latest news: Lexicon Pharmaceuticals, Inc.

Last Transcript: Lexicon Pharmaceuticals, Inc.

Analysts' recommendations: Lexicon Pharmaceuticals, Inc.

Press Releases: Lexicon Pharmaceuticals, Inc.

News in other languages: Lexicon Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Lexicon Pharmaceuticals, Inc.

ETFs: Lexicon Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12/01	Lexicon Pharmaceuticals Publishes Relief is Possible, Ensuring Access to Effective Treatments for Chronic Pain	AQ
12/01	Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference	AQ
09/01	Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”	AQ
07/01	Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
11/12	Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 Reinforcing the Scientific Rationale for LX9851	AQ

28/25/28	Novo Nordisk comprará licencia de medicamento de Lexicon en acuerdo por hasta 1.000 millones de dólares
28/25/28	Novo Nordisk : accord de licence avec l'américain Lexicon
10/23/10	MÄRKTE USA/Sinkende Renditen treiben Aktien weiter nach oben
10/23/10	MÄRKTE USA/Aktien starten gut behauptet - Anleihen fest
10/23/10	MÄRKTE USA/Aktien gut behauptet erwartet - Anleihen fest

1 day	+7.03%
1 week	+17.09%
Current month	+19.13%
1 month	+16.10%
3 months	-3.52%
6 months	+11.38%
Current year	+19.13%

1 week	1.18	1.4
1 month	1.11	1.4
Current year	1.11	1.4
1 year	0.28	1.66
3 years	0.28	3.79
5 years	0.28	9.65
10 years	0.28	19.62

Manager	Title	Age	Since
Michael Exton CEO	Chief Executive Officer	56	08/07/2024
Scott Coiante DFI	Director of Finance/CFO	59	02/01/2025
Craig Granowitz CTO	Chief Tech/Sci/R&D Officer	62	02/08/2021

Director	Title	Age	Since
Samuel Barker CHM	Chairman	83	01/01/2005
Ray Debbane CHM	Chairman	71	27/02/2012
Christopher Sobecki BRD	Director/Board Member	67	28/08/2007

Name		Varia. Jan 1.	Weight	AuM
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD		+5.41%	0%	7 M€
SECTOR ROTATION ETF - USD		+0.85%	0%	2,091 M€

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
LEXICON PHARMACEUTICALS, INC.	+7.03%	+17.09%	+98.55%	-38.57%	50Cr
ARGENX SE	-1.82%	+1.37%	+7.35%	+92.26%	4.92TCr
WUXI APPTEC CO., LTD.	+0.71%	+5.27%	+96.79%	+10.10%	4.46TCr
INSMED INCORPORATED	+1.35%	-8.27%	+122.62%	+761.37%	3.44TCr
BIONTECH SE	+2.76%	+9.16%	-2.62%	-23.82%	2.74TCr
WUXI BIOLOGICS (CAYMAN) INC.	-4.83%	+0.75%	+102.46%	-46.22%	2.11TCr
GENMAB A/S	-6.38%	-5.64%	+35.10%	-24.67%	2.09TCr
AKESO, INC.	-3.06%	-6.98%	+96.15%	+150.64%	1.43TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.45%	-8.38%	+167.14%	-	1.42TCr
SUMMIT THERAPEUTICS INC.	-1.33%	-13.41%	-10.46%	+282.92%	1.31TCr
Average	-1.10%	+1.20%	+71.31%	+129.34%	2.4TCr
Weighted average by Cap.	-1.27%	+0.54%	+64.15%	+154.79%

	2025 *	2026 *
Net sales	4.75Cr 4.09Cr 3.81Cr 3.55Cr 6.6Cr 430.6Cr 7.1Cr 44Cr 17Cr 205.4Cr 18Cr 17Cr 749.99Cr	2.1Cr 1.81Cr 1.68Cr 1.57Cr 2.92Cr 190.21Cr 3.14Cr 19Cr 7.63Cr 91Cr 7.86Cr 7.7Cr 331.29Cr
Net income	-6.27Cr -5.4Cr -5.03Cr -4.68Cr -8.72Cr -568.68Cr -9.38Cr -58Cr -23Cr -271.26Cr -24Cr -23Cr -990.49Cr	-11Cr -9.18Cr -8.55Cr -7.96Cr -15Cr -966.43Cr -16Cr -98Cr -39Cr -460.98Cr -40Cr -39Cr -1.68TCr
Net Debt	-	-